Cargando…
Patient reported outcomes for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG): listening to what matters for the patients and health professionals
BACKGROUND: Congenital disorders of glycosylation (CDG) are a growing group of rare genetic disorders. The most common CDG is phosphomannomutase 2 (PMM2)-CDG which often has a severe clinical presentation and life-limiting consequences. There are no approved therapies for this condition. Also, there...
Autores principales: | Pascoal, C., Ferreira, I., Teixeira, C., Almeida, E., Slade, A., Brasil, S., Francisco, R., Ligezka, A. N., Morava, E., Plotkin, H., Jaeken, J., Videira, P. A., Barros, L., dos Reis Ferreira, V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618201/ https://www.ncbi.nlm.nih.gov/pubmed/36309700 http://dx.doi.org/10.1186/s13023-022-02551-y |
Ejemplares similares
-
Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment
por: Serrano, Mercedes, et al.
Publicado: (2015) -
Anesthetic management of a child with phosphomannomutase-2 congenital disorder of glycosylation (PMM2-CDG)
por: Sakai, Wataru, et al.
Publicado: (2017) -
Natural Killer Cell Receptors and Cytotoxic Activity in Phosphomannomutase 2 Deficiency (PMM2-CDG)
por: García-López, Roberto, et al.
Publicado: (2016) -
Genotype-Phenotype Correlations in PMM2-CDG
por: Vaes, Laurien, et al.
Publicado: (2021) -
Dietary mannose supplementation in phosphomannomutase 2 deficiency (PMM2-CDG)
por: Taday, Roman, et al.
Publicado: (2020)